{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:44:02Z","timestamp":1793421842890,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ijcard.2022.10.014","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T11:53:43Z","timestamp":1665402823000},"page":"271-278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Safety and efficacy of ranolazine in hypertrophic cardiomyopathy: Real-world experience in a National Referral Center"],"prefix":"10.1016","volume":"370","author":[{"given":"Alessia","family":"Argir\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Zampieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo-Lupo","family":"Dei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Ferrantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Marchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Tomberli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Favilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Passantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Zocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Tassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Gabriele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Maurizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Marchionni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Coppini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ijcard.2022.10.014_bb0005","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and Management of Hypertrophic Cardiomyopathy. Longo DL, ed","volume":"379","author":"Maron","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.ijcard.2022.10.014_bb0010","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"142","author":"Writing Committee Members","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ijcard.2022.10.014_bb0015","doi-asserted-by":"crossref","DOI":"10.1111\/micc.12656","article-title":"Coronary microvascular dysfunction in hypertrophic cardiomyopathy: pathophysiology, assessment, and clinical impact","volume":"28","author":"Aguiar Rosa","year":"2021","journal-title":"Microcirculation."},{"issue":"8","key":"10.1016\/j.ijcard.2022.10.014_bb0020","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.CIR.0000139333.83620.5D","article-title":"Electrophysiological effects of Ranolazine, a novel antianginal agent with antiarrhythmic properties","volume":"110","author":"Antzelevitch","year":"2004","journal-title":"Circulation."},{"issue":"Suppl I","key":"10.1016\/j.ijcard.2022.10.014_bb0025","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/eurheartj\/6.suppl_i.i3","article-title":"Inhibition of late (sustained\/persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function","volume":"6","author":"Belardinellia","year":"2004","journal-title":"Eur. Heart J. Suppl."},{"issue":"5","key":"10.1016\/j.ijcard.2022.10.014_bb0030","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.112.134932","article-title":"Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy","volume":"127","author":"Coppini","year":"2013","journal-title":"Circulation."},{"issue":"1","key":"10.1016\/j.ijcard.2022.10.014_bb0035","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004124","article-title":"Efficacy of Ranolazine in patients with symptomatic hypertrophic cardiomyopathy: the RESTYLE-HCM randomized, double-blind, placebo-controlled study","volume":"11","author":"Olivotto","year":"2018","journal-title":"Circ. Heart Fail."},{"issue":"5","key":"10.1016\/j.ijcard.2022.10.014_bb0040","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1161\/CIRCULATIONAHA.110.937136","volume":"122","author":"Scirica","year":"2010","journal-title":"Circulation."},{"issue":"1","key":"10.1016\/j.ijcard.2022.10.014_bb0045","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/europace\/euu217","article-title":"Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial","volume":"17","author":"Scirica","year":"2015","journal-title":"Europace."},{"key":"10.1016\/j.ijcard.2022.10.014_bb0050","first-page":"1","article-title":"Ranolazine for angina in hypertrophic cardiomyopathy","volume":"2018","author":"Amin","year":"2018","journal-title":"Case Rep. Cardiol."},{"issue":"16","key":"10.1016\/j.ijcard.2022.10.014_bb0055","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.jacc.2016.07.758","article-title":"Ranolazine for treatment of angina or dyspnea in hypertrophic cardiomyopathy patients (RHYME)","volume":"68","author":"Gentry","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"39","key":"10.1016\/j.ijcard.2022.10.014_bb0060","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","year":"2014","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.ijcard.2022.10.014_bb0065","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2174\/1573403X10666140514103612","article-title":"The measurement of the QT interval","volume":"10","author":"Postema","year":"2014","journal-title":"CCR."},{"issue":"13","key":"10.1016\/j.ijcard.2022.10.014_bb0070","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.ehj.2004.03.022","article-title":"Nonsustained ventricular tachycardia: where do we stand?","volume":"25","author":"Katritsis","year":"2004","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.ijcard.2022.10.014_bb0075","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"10.1016\/j.ijcard.2022.10.014_bb0080","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ijcard.2016.06.044","article-title":"Prognostic role of stress echocardiography in hypertrophic cardiomyopathy: the international stress Echo registry","volume":"219","author":"Ciampi","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2022.10.014_bb0085","article-title":"Sex-related differences in exercise performance and outcome of patients with hypertrophic cardiomyopathy","author":"Ghiselli","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"7","key":"10.1016\/j.ijcard.2022.10.014_bb0090","first-page":"795","article-title":"Electrophysiological and contractile effects of disopyramide in patients with obstructive hypertrophic cardiomyopathy","volume":"4","author":"Coppini","year":"2019","journal-title":"JACC"},{"issue":"8","key":"10.1016\/j.ijcard.2022.10.014_bb0095","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.ijcard.2022.10.014_bb0100","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","article-title":"Effects of Ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic AnginaA randomized controlled trial","volume":"291","author":"Chaitman","year":"2004","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ijcard.2022.10.014_bb0105","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","article-title":"Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina","volume":"43","author":"Chaitman","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2022.10.014_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2020.05.020","article-title":"Long-term (3 years) outcomes of Ranolazine therapy for refractory angina pectoris (from the Ranolazine refractory registry)","volume":"129","author":"Storey","year":"2020","journal-title":"Am. J. Cardiol."},{"issue":"10253","key":"10.1016\/j.ijcard.2022.10.014_bb0115","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.ijcard.2022.10.014_bb0120","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.jacc.2021.08.073","article-title":"Effect of \u03b2-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction","volume":"78","author":"Palau","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"15","key":"10.1016\/j.ijcard.2022.10.014_bb0125","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.jacc.2016.07.751","article-title":"Mechanisms of myocardial ischemia in hypertrophic cardiomyopathy","volume":"68","author":"Raphael","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2022.10.014_bb0130","article-title":"Myocardial blood flow in patients with hypertrophic cardiomyopathy receiving perindopril (CARAPaCE): a pilot study","author":"De Gregorio","year":"2020","journal-title":"J. Cardiovas. Med."},{"issue":"19","key":"10.1016\/j.ijcard.2022.10.014_bb0135","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/eurheartj\/ehv647","article-title":"A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve","volume":"37","author":"Bairey Merz","year":"2016","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.ijcard.2022.10.014_bb0140","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.amjcard.2013.02.045","article-title":"Effects of Ivabradine and Ranolazine in patients with microvascular angina pectoris","volume":"112","author":"Villano","year":"2013","journal-title":"Am. J. Cardiol."},{"issue":"7","key":"10.1016\/j.ijcard.2022.10.014_bb0145","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005407","article-title":"Pathogenesis of hypertrophic cardiomyopathy is mutation rather than disease specific: a comparison of the cardiac troponin T E163R and R92Q mouse models","volume":"6","author":"Ferrantini","year":"2017","journal-title":"JAHA."},{"issue":"1","key":"10.1016\/j.ijcard.2022.10.014_bb0150","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004572","article-title":"Evolving story of clinical trials in hypertrophic cardiomyopathy. Circ","volume":"11","author":"Elliott","year":"2018","journal-title":"Heart Fail."},{"issue":"6","key":"10.1016\/j.ijcard.2022.10.014_bb0155","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.hrthm.2021.01.019","article-title":"Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: twenty years with the implantable cardioverter-defibrillator","volume":"18","author":"Maron","year":"2021","journal-title":"Heart Rhythm."},{"issue":"5","key":"10.1016\/j.ijcard.2022.10.014_bb0160","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.112.134932","article-title":"Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy","volume":"127","author":"Coppini","year":"2013","journal-title":"Circulation."},{"issue":"9","key":"10.1016\/j.ijcard.2022.10.014_bb0165","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jacc.2009.04.072","article-title":"The case for myocardial ischemia in hypertrophic cardiomyopathy","volume":"54","author":"Maron","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.ijcard.2022.10.014_bb0170","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.hrcr.2018.03.004","article-title":"Hypertrophic cardiomyopathy: ischemia progressing to ventricular fibrillation","volume":"4","author":"Rochelson","year":"2018","journal-title":"HeartRhythm Case Rep."},{"issue":"2","key":"10.1016\/j.ijcard.2022.10.014_bb0175","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0735-1097(03)00582-5","article-title":"Hypertrophic cardiomyopathy and diastolic dysfunction**editorials published in the journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology","volume":"42","author":"Shah","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.ijcard.2022.10.014_bb0180","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1161\/CIRCHEARTFAILURE.112.967026","article-title":"Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circ","volume":"5","author":"Olivotto","year":"2012","journal-title":"Heart Fail."},{"issue":"21","key":"10.1016\/j.ijcard.2022.10.014_bb0185","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1113\/jphysiol.2012.234252","article-title":"Myosin-driven rescue of contractile reserve and energetics in mouse hearts bearing familial hypertrophic cardiomyopathy-associated mutant troponin T is mutation-specific: cost of contraction of remodelled mutant cTnT hearts","volume":"590","author":"He","year":"2012","journal-title":"J. Physiol."},{"issue":"12","key":"10.1016\/j.ijcard.2022.10.014_bb0190","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1172\/JCI118740","article-title":"Altered cardiac troponin T in vitro function in the presence of a mutation implicated in familial hypertrophic cardiomyopathy","volume":"97","author":"Lin","year":"1996","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.ijcard.2022.10.014_bb0195","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1074\/jbc.M006746200","article-title":"Abnormal contractile function in transgenic mice expressing a familial hypertrophic cardiomyopathy-linked troponin T (I79N) mutation","volume":"276","author":"Miller","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"24","key":"10.1016\/j.ijcard.2022.10.014_bb0200","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1016\/j.jacc.2014.09.059","article-title":"Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations","volume":"64","author":"Coppini","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcard.2022.10.014_bb0205","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/CIRCRESAHA.111.258251","article-title":"Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity","volume":"110","author":"Lovelock","year":"2012","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcard.2022.10.014_bb0210","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijcard.2016.04.168","article-title":"Long-term administration of ranolazine attenuates diastolic dysfunction and adverse myocardial remodeling in a model of heart failure with preserved ejection fraction","volume":"217","author":"De Angelis","year":"2016","journal-title":"Int. J. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcard.2022.10.014_bb0215","first-page":"H867","article-title":"Ranolazine improves diastolic function in spontaneously hypertensive rats","volume":"306","author":"Williams","year":"2014","journal-title":"Am. J. Phys. Heart Circ. Phys."},{"issue":"2","key":"10.1016\/j.ijcard.2022.10.014_bb0220","first-page":"115","article-title":"RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction. JACC","volume":"1","author":"Maier","year":"2013","journal-title":"Heart Fail."},{"key":"10.1016\/j.ijcard.2022.10.014_bb0225","series-title":"Microvascular Function Is Selectively Impaired in Patients With Hypertrophic Cardiomyopathy and Sarcomere Myofilament Gene Mutations","first-page":"10","volume":"58(8)","author":"Olivotto","year":"2011"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527322015236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527322015236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T21:01:57Z","timestamp":1759093317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527322015236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":45,"alternative-id":["S0167527322015236"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2022.10.014","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of ranolazine in hypertrophic cardiomyopathy: Real-world experience in a National Referral Center","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2022.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}